{"id":"ly450139","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Skin rash"},{"rate":null,"effect":"Cognitive/neurological effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gamma-secretase is an intramembrane protease complex responsible for the final cleavage step in amyloid-beta generation. By inhibiting this enzyme, LY450139 decreases amyloid-beta production in the brain, which is hypothesized to slow cognitive decline in Alzheimer's disease. This approach targets the amyloid hypothesis of neurodegeneration.","oneSentence":"LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:55.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease (mild cognitive impairment and mild dementia stages)"}]},"trialDetails":[{"nctId":"NCT00594568","phase":"PHASE3","title":"Effect of LY450139 on the Long Term Progression of Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-03","conditions":"Alzheimer's Disease","enrollment":1537},{"nctId":"NCT00762411","phase":"PHASE3","title":"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-09","conditions":"Alzheimer's Disease","enrollment":1111},{"nctId":"NCT01035138","phase":"PHASE3","title":"A Study of Semagacestat for Alzheimer's Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-12","conditions":"Alzheimer's Disease","enrollment":180},{"nctId":"NCT00765115","phase":"PHASE1","title":"A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-07","conditions":"Alzheimer Disease","enrollment":27},{"nctId":"NCT00244322","phase":"PHASE2","title":"Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-10","conditions":"Alzheimer's Disease","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["semagacestat","Semagacestat"],"phase":"phase_3","status":"active","brandName":"LY450139","genericName":"LY450139","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY450139 is a gamma-secretase inhibitor that reduces the production of amyloid-beta by blocking the cleavage of amyloid precursor protein. Used for Alzheimer's disease (mild cognitive impairment and mild dementia stages).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}